Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Zusammenfassung

Clin Infect Dis . 2018 Sep 12;67(10):1477–1492. doi: 10.1093/cid/ciy585 Search in PMC Search in PubMed View in NLM Catalog Add to search Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection AASLD-IDSA HCV Guidance Panel 1 Author information Article notes Copyright and License information 1 HCV guidance panel members and their affiliations are listed at the end of the article. ✉ Correspondence: A. Y. Kim, Massachusetts Genera

Kerninformationen

September 2017, prompted primarily by approval of new direct-acting antiviral agents and expansion of the guidance’s scope. This update summarizes the latest release of the HCV guidance and focuses on new or amended recommendations since the previous September 2015 print publication. The recommendat...

se of HCV management. This summary focuses on updated recommendations related to antiviral therapy as of 1 May 2018. Since the last published document [ 20 ], certain previously recommended regimens have been downgraded to alternative status due to considerations such as pill burden, use of ribaviri...

factors (treatment naive vs experienced, cirrhosis status, comorbidities) and viral characteristics (genotype [GT], subtype, resistance-associated substitutions [RASs]). Recommended regimens are considered equivalent. Alternative regimens are effective but, relative to recommended regimens, have pot...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen